DOI:
10.1055/s-00000030
Der Klinikarzt
LinksClose Window
References
Harrison C, Kiladijan JJ, Al-Ali HK et al.
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.
N Engl J Med 2012;
366: 787-798
We do not assume any responsibility for the contents of the web pages of other providers.